article thumbnail

Qure.ai partners with Roche's Startup Creasphere

AuntMinnie

plans to collaborate with Roche Diagnostics Asia Pacific under that company's Startup Creasphere Asia-Pacific (APAC) Batch Four initiative. The partnership will make Qure.ai's medical imaging offerings available in the region -- particularly for cardiovascular and lung conditions -- through Roche's diagnostic portfolio.

article thumbnail

Lunit's AI-Powered Mammography Analysis Solution Achieves Comparable Diagnostic Performance with Human Readers

Imaging Technology

milla1cf Wed, 09/13/2023 - 15:56 September 13, 2023 — Lunit , a leading provider of AI- powered solutions for cancer diagnostics and therapeutics, has unveiled the results of a collaborative study with Dr. Yan Chen , Ph.D., Professor of digital screening at the University of Nottingham, United Kingdom.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UC Berkeley researchers develop CT-based 'virtual stress test' for BMD

AuntMinnie

Preventive Services Task Force (USPSTF) is currently reviewing its 2018 guidance for osteoporosis screening, lead researcher Tony Keaveny, PhD, of Berkeley BioMechanics Laboratory, told AuntMinnie.com. Diagnostics. In 2018 O.N. Diagnostics plans to submit further clearance documents to the U.S. Physicians send O.N.

X-ray 105
article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

article thumbnail

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,

article thumbnail

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Chief Executive Officer of Blue Earth Diagnostics.

article thumbnail

FAPI-PET shows value in staging lung cancer patients

AuntMinnie

Fibroblast activation protein inhibitor (FAPI) PET/CT shows excellent diagnostic accuracy for detecting lymph node metastases in lung cancer patients, according to a study published October 14 in Academic Radiology. FAPI-PET/CT] holds the potential to optimize the need for invasive diagnostic procedures,” the group concluded.